Forma Therapeutics Holdings (Forma Therapeutics Holdings) Book Value per Share : $8.67 (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings Book Value per Share?

Forma Therapeutics Holdings's book value per share for the quarter that ended in Jun. 2022 was $8.67.

During the past 12 months, Forma Therapeutics Holdings's average Book Value Per Share Growth Rate was -29.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Forma Therapeutics Holdings's current price is $20.01. Its book value per share for the quarter that ended in Jun. 2022 was $8.67. Hence, today's PB Ratio of Forma Therapeutics Holdings is 2.31.

During the past 4 years, the highest P/B Ratio of Forma Therapeutics Holdings was 4.94. The lowest was 0.50. And the median was 2.32.

Forma Therapeutics Holdings Book Value per Share Historical Data

The historical data trend for Forma Therapeutics Holdings's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forma Therapeutics Holdings Book Value per Share Chart

Forma Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Book Value per Share

-4.79

0.49

13.72

10.51

Forma Therapeutics Holdings Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Book Value per Share	Get a 7-Day Free Trial										12.24	11.46	10.51	9.66	8.67

Competitive Comparison of Forma Therapeutics Holdings's Book Value per Share

For the Biotechnology subindustry, Forma Therapeutics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forma Therapeutics Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forma Therapeutics Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Forma Therapeutics Holdings's PB Ratio falls into.

Forma Therapeutics Holdings Book Value per Share Calculation

Forma Therapeutics Holdings's Book Value Per Share for the fiscal year that ended in Dec. 2021 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(498.36	-	0.00)	/	47.40
	=	10.51

Forma Therapeutics Holdings's Book Value Per Share for the quarter that ended in Jun. 2022 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(414.49	-	0.00)	/	47.83
	=	8.67

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Forma Therapeutics Holdings (NAS:FMTX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Forma Therapeutics Holdings Book Value per Share Related Terms

Thank you for viewing the detailed overview of Forma Therapeutics Holdings's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472

Website

https://www.formatherapeutics.com

Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.

Executives

Agustin Melian	officer: EVP, Research & Development	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser	officer: SVP, Commercial Officer	C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee	director, officer: President and CEO	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook	officer: SVP, Chief Scientific Officer
Patrick F. Kelly	officer: SVP, Chief Medical Officer	C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog	officer: SVP, Chief Financial Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina	director	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop	officer: Chief Technology Officer	675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md	director	600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans	director
Frederick Wayne A.i.	director	500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116